Oxytocin Administration in Low-Risk Women, a Retrospective Analysis of Birth and Neonatal Outcomes.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
20 04 2021
Historique:
received: 30 03 2021
revised: 16 04 2021
accepted: 16 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 21 5 2021
Statut: epublish

Résumé

In recent years, higher than the recommended rate of oxytocin use has been observed among low-risk women. This study examines the relationship between oxytocin administration and birth outcomes in women and neonates. A retrospective analysis of birth and neonatal outcomes for women who received oxytocin versus those who did not. The sample included 322 women with a low-risk pregnancy. Oxytocin administration was associated with cesarean section (aOR 4.81, 95% CI: 1.80-12.81), instrumental birth (aOR 3.34, 95% CI: 1.45-7.67), episiotomy (aOR 3.79, 95% CI: 2.20-6.52) and length of the second stage (aOR 00:18, 95% CI: 00:04-00:31). In neonatal outcomes, oxytocin in labor was associated with umbilical artery pH ≤ 7.20 (OR 3.29, 95% CI: 1.33-8.14). Admission to neonatal intensive care unit (OR 0.56, 95% CI: 0.22-1.42), neonatal resuscitation (OR 1.04, 95% CI: 0.22-1.42), and Apgar score <7 (OR 0.48, 95% CI: 0.17-1.33) were not associated with oxytocin administration during labor. Oxytocin administration during labor for low-risk women may lead to worse birth outcomes with an increased risk of instrumental birth and cesarean, episiotomy and the use of epidural analgesia for pain relief. Neonatal results may be also worse with an increased proportion of neonates displaying an umbilical arterial pH ≤ 7.20.

Sections du résumé

BACKGROUND
In recent years, higher than the recommended rate of oxytocin use has been observed among low-risk women. This study examines the relationship between oxytocin administration and birth outcomes in women and neonates.
METHODS
A retrospective analysis of birth and neonatal outcomes for women who received oxytocin versus those who did not. The sample included 322 women with a low-risk pregnancy.
RESULTS
Oxytocin administration was associated with cesarean section (aOR 4.81, 95% CI: 1.80-12.81), instrumental birth (aOR 3.34, 95% CI: 1.45-7.67), episiotomy (aOR 3.79, 95% CI: 2.20-6.52) and length of the second stage (aOR 00:18, 95% CI: 00:04-00:31). In neonatal outcomes, oxytocin in labor was associated with umbilical artery pH ≤ 7.20 (OR 3.29, 95% CI: 1.33-8.14). Admission to neonatal intensive care unit (OR 0.56, 95% CI: 0.22-1.42), neonatal resuscitation (OR 1.04, 95% CI: 0.22-1.42), and Apgar score <7 (OR 0.48, 95% CI: 0.17-1.33) were not associated with oxytocin administration during labor.
CONCLUSIONS
Oxytocin administration during labor for low-risk women may lead to worse birth outcomes with an increased risk of instrumental birth and cesarean, episiotomy and the use of epidural analgesia for pain relief. Neonatal results may be also worse with an increased proportion of neonates displaying an umbilical arterial pH ≤ 7.20.

Identifiants

pubmed: 33924137
pii: ijerph18084375
doi: 10.3390/ijerph18084375
pmc: PMC8074312
pii:
doi:

Substances chimiques

Oxytocin 50-56-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Midwifery Womens Health. 2014 Jan-Feb;59(1):35-42: quiz 108
pubmed: 24472136
Midwifery. 2018 Jul;62:214-219
pubmed: 29715598
Medicine (Baltimore). 2019 Feb;98(8):e14284
pubmed: 30813131
Cochrane Database Syst Rev. 2018 May 21;5:CD000331
pubmed: 29781504
Am J Obstet Gynecol. 2009 Jan;200(1):35.e1-6
pubmed: 18667171
Midwifery. 2015 Mar;31(3):e36-42
pubmed: 25595350
Int J Gynaecol Obstet. 2019 Jul;146(1):65-73
pubmed: 31173359
Midwifery. 2014 Mar;30(3):364-70
pubmed: 23684697
J Midwifery Womens Health. 2017 Jul;62(4):425-433
pubmed: 28703909
Acta Obstet Gynecol Scand. 2009;88(4):402-7
pubmed: 19330572
Paediatr Perinat Epidemiol. 2001 Apr;15(2):131-8
pubmed: 11383577
Am J Obstet Gynecol. 2019 Mar;220(3):273.e1-273.e11
pubmed: 30716284
Am J Obstet Gynecol. 2007 Apr;196(4):313.e1-6
pubmed: 17403401
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD006167
pubmed: 23440804
J Matern Fetal Neonatal Med. 2008 Aug;21(8):517-21
pubmed: 18609353
Obstet Gynecol. 2000 Jun;95(6 Pt 1):917-22
pubmed: 10831992
Acta Obstet Gynecol Scand. 2008;87(7):745-50
pubmed: 18607817
Clin Obstet Gynecol. 2014 Jun;57(2):343-62
pubmed: 24662771
J Neuroendocrinol. 2014 Jun;26(6):356-69
pubmed: 24888645
Midwifery. 2020 Sep;88:102752
pubmed: 32521407
Evid Rep Technol Assess (Full Rep). 2009 Mar;(176):1-257
pubmed: 19408970
Acta Obstet Gynecol Scand. 2013 Feb;92(2):198-203
pubmed: 23157554
Aust N Z J Obstet Gynaecol. 2020 Jun;60(3):336-343
pubmed: 31486065
Lancet. 2016 Oct 29;388(10056):2176-2192
pubmed: 27642019
Birth. 2011 Dec;38(4):317-26
pubmed: 22112332
Cochrane Database Syst Rev. 2013 Jul 13;(7):CD007201
pubmed: 23853046
Am J Obstet Gynecol. 2012 Jun;206(6):486.e1-9
pubmed: 22520652
Acta Obstet Gynecol Scand. 2006;85(9):1094-8
pubmed: 16929414
Acta Obstet Gynecol Scand. 2016 Mar;95(3):355-61
pubmed: 26576009
J Gynecol Obstet Hum Reprod. 2017 Jun;46(6):509-521
pubmed: 28473291
J Midwifery Womens Health. 2020 Jan;65(1):142-148
pubmed: 31207071
Medicina (Kaunas). 2019 Jul 09;55(7):
pubmed: 31324024
Arch Gynecol Obstet. 2017 May;295(5):1175-1183
pubmed: 28357560
J Gynecol Obstet Biol Reprod (Paris). 2013 Nov;42(7):662-70
pubmed: 23570744
Acta Obstet Gynecol Scand. 2010;89(1):39-48
pubmed: 19961278
MCN Am J Matern Child Nurs. 2018 May/Jun;43(3):133-138
pubmed: 29489527
J Midwifery Womens Health. 2011 May-Jun;56(3):214-21
pubmed: 21535370
Rev Lat Am Enfermagem. 2016;24:e2744
pubmed: 27463109
Acta Obstet Gynecol Scand. 2012 Feb;91(2):198-203
pubmed: 21995778
BMC Pregnancy Childbirth. 2018 Mar 27;18(1):76
pubmed: 29587658
Cochrane Database Syst Rev. 2020 Jul 15;7:CD004945
pubmed: 32666584
PLoS One. 2018 May 17;13(5):e0197791
pubmed: 29772012
Aust N Z J Obstet Gynaecol. 2011 Apr;51(2):151-7
pubmed: 21466518

Auteurs

Xavier Espada-Trespalacios (X)

Department of Obstetrics and Gynecology, Hospital General de Granollers, Avinguda Francesc Ribas s/n, 08402 Granollers, Spain.
Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Doctor Aiguader 88, 08003 Barcelona, Spain.
Research Group in Global Health, Gender and Society (GHenderS), Universitat Ramon Llull, Carrer Padilla 326, 08025 Barcelona, Spain.

Felipe Ojeda (F)

Department of Obstetrics and Gynecology, Hospital General de Granollers, Avinguda Francesc Ribas s/n, 08402 Granollers, Spain.

Mercedes Perez-Botella (M)

Research in Childbirth and Health Unit (ReaRH), University of Central Lancashire, Preston PR1 2HE, UK.
Department of Neonatology, Hospital General de Granollers, Avinguda Francesc Ribas s/n, 08402 Granollers, Spain.

Raimon Milà Villarroel (R)

School of Health Sciences Blanquerna, Universitat Ramon Llull, Carrer Padilla 326, 08025 Barcelona, Spain.

Montserrat Bach Martinez (M)

Department of Obstetrics and Gynecology, Hospital General de Granollers, Avinguda Francesc Ribas s/n, 08402 Granollers, Spain.

Helena Figuls Soler (H)

Department of Obstetrics and Gynecology, Hospital General de Granollers, Avinguda Francesc Ribas s/n, 08402 Granollers, Spain.

Israel Anquela Sanz (I)

School of Health Sciences Blanquerna, Universitat Ramon Llull, Carrer Padilla 326, 08025 Barcelona, Spain.

Pablo Rodríguez Coll (P)

Obstetric Care Area, Hospital Germans Trias i Pujol, Carretera de Canyet s/n, 08916 Badalona, Spain.

Ramon Escuriet (R)

Research Group in Global Health, Gender and Society (GHenderS), Universitat Ramon Llull, Carrer Padilla 326, 08025 Barcelona, Spain.
Catalan Health Service, Government of Catalonia, Travessera de les Corts 131, 08028 Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH